Patients are flocking to the region in search of good quality, alternative healthcare treatments, while biopharma firms are making forays into new, emerging markets
[HAIKOU] Within the Chinese healthcare sphere, patients and biopharmaceutical companies have something in common – they are increasingly seeing South-east Asia as a key region.
Patients are flocking to the region in search of good quality, alternative healthcare treatments, while biopharma firms are making forays into new, emerging markets.
Medical tourism and biopharmaceutical manufacturing are key growth opportunities for companies in China and South-east Asia, as Chinese tourists and biopharma investments flow down to Asean, said healthcare players and observers at a panel discussion in Haikou, China, on Wednesday (Oct 16).
This post was originally published on here
